Asset
Surabgene Lomparvovec
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03066258 | phase1_2 | completed | 2017-03-29 | 2019-11-24 | REGENXBIO Inc. | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial |
FDA applications (0)
This company has no applications containing this asset.